Longeveron said the China National Intellectual Property Administration granted Patent No. 2026031300230720 covering potency assay methods to assess human mesenchymal stem cells derived from bone marrow, adipose tissue, peripheral blood, lung, heart, amniotic fluid, inner organs, amniotic membrane, umbilical cord or placenta, or differentiated from induced pluripotent stem cells.
The patent provides rights in China through 2041, assuming annuity fees are paid. The company claims the issuance adds to its international portfolio of 52 patents, which protect its clinical programs and products.
According to the company, potency assays are a crucial element for approved cell-based therapy products. Longeveron noted that its lead investigational product, laromestrocel, has been studied in Alzheimer’s disease, aging-related frailty and hypoplastic left heart syndrome, and that a potentially pivotal phase 2b trial in HLHS is underway with results expected in the third quarter of 2026.
The company claims laromestrocel development programs have received multiple FDA designations and said the patent is intended to support development and potential regulatory filings in China.
